Changing Prostate Cancer
"What does my diagnosis of prostate cancer mean?" For a century, our doctors and scientists here at the Brady have worked to answer that question on every level. Our discoveries have transformed the way organ-confined disease is treated and continue to bring new hope to men with metastatic disease. Our Active Surveillance program, pioneered by Bal Carter, has helped many men with slow-growing, small-volume disease avoid surgery safely; and now work by uropathologist Jonathan Epstein is actually changing the way the disease is diagnosed. For example, Gleason score 3 +3 is its own category, Grade Group 1; Gleason 3 + 4 is Grade Group 2, and Gleason 4 + 3 is Grade group 3. There are only five groups, and Gleason score 8 is a distinct group, because those men have different disease than men with Gleason scores 9 and 10. The World Health Organization has accepted this system, and it will soon be used at hospitals everywhere. In this exciting issue of Discovery, we're proud to tell you about our latest work in immunotherapy, in dietary prevention, our work with robots, our advances in understanding genetic risk, our successes in molecular biology, and other breakthroughs including the successful imaging of individual cells of prostate cancer throughout the body — which opens up new targets for treating metastatic disease.
We also bring to you our continuing advances in diagnosis, treatment and active surveillance of kidney cancer, in refining treatment for bladder cancer, and a new advance in the laparoscopic treatment of testicular cancer.
Your generosity makes us able to do more, so that we can continue to improve the lives of people with urological diseases. Thank you for being our partners in discovery.
Alan W. Partin, M.D., Ph.D.
Jakurski Family Director and
Chairman of The Brady Urological Institute